Schizophrenia. Schizophrenia
Conditions
Interventions
In addition to antipsychotic medication, intervention 1 received daily aspirin produced by Daroupakhsh Co for 6 weeks at a dose of 500 mg, while intervention 2, in addition to antipsychotic medication
Treatment - Drugs
Sponsors
Isfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: The inclusion criteria were age of 18-65 years old; diagnosed with schizophrenia based on clinical interview and DSM-IV-TR; patients with 2 years of history since the onset of the disease. The exclusion criteria were unwillingness to participate in the study; failure to see doctor for follow-up for whatever reason; unstable medical illness and medical history; contraindications for use of aspirin, such as asthma or seasonal allergies, ulcers, kidney disease, active bleeding or clotting of blood disorders such as hemophilia or bleeding, gout, nasal polyps; chronic use of NSAID; concomitant use of corticosteroids for any reason and maternity.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PANSS test. Timepoint: On the first day, at the end of the sixth week and one month after cessation of aspirin or placebo. Method of measurement: PANSS test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAsefeh Mojdeh
Isfahan University of Medical Sciences
Outcome results
None listed